Dr. Xie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st Street SW
Rochester, MN 55905
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2017 - 2020
Yale-New Haven Medical CenterResidency, Internal Medicine, 2014 - 2017
Cleveland Clinic Lerner College of MedicineClass of 2014, MD
Princeton UniversityPhD, Organic Chemistry, 2004 - 2009- Fudan UniversityBS, Chemistry, 2000 - 2004
Certifications & Licensure
FL State Medical License 2020 - 2026
MN State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC.Christina Wu, Reetesh K Pai, Heidi Kosiorek, Imon Banerjee, Ashlyn Pfeiffer
Clinical Cancer Research. 2024-05-01 - 1 citationsPlasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies.Mojun Zhu, William R Taylor, Douglas W Mahoney, Sara S Then, Calise K Berger
Cancers. 2023-12-09 - 1 citationsSelecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer.Oluwadunni E Emiloju, Mojun Zhu, Hao Xie, Zhaohui Jin, Frank A Sinicrope
Current Treatment Options in Oncology. 2023-12-01
Lectures
- Phase II trial of trifluridine/tipiracil and irinotecan for the treatment of advanced refractory biliary tract cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients.2019 ASCO Annual Meeting - 6/1/2019
- Methylated DNA markers (MDMs) in primary (pCRC) and metastatic colorectal cancers (mCRC).2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
- Liquid Biopsies May Ease Enrollment in Clinical TrialsNovember 6th, 2020
Study Finds DNA Markers May Be Valuable in Early Detection of Colorectal CancerMay 31st, 2019
Colorectal Cancer: Younger Patients Fare WorseJune 30th, 2023
Other Languages
- Chinese (Mandarin)
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
